# Salt Selection & Cocrystal Screening: The Chemical Engineering Guide to Overcoming API Insoluble Traps (pKa Rule & Phase Diagrams)

# An Advanced Solid-State Engineering Guide to the $\Delta\text{p}K_a$ Continuum, Congruent vs. Incongruent Ternary Phase Solubilities, In Vivo Disproportionation, and Industrial Counterion Scale-Up

# Executive Summary & Industrial Stakes

Over $40\%$ of commercially marketed drugs and up to $75\%$ of pipeline New Chemical Entities (NCEs) exhibit aqueous solubilities below $0.1\,\text{mg/mL}$, placing them firmly in BCS Class II (low solubility, high permeability) or BCS Class IV (low solubility, low permeability). For these molecules, gastrointestinal absorption is limited by dissolution rate.

When an API free base or free acid exhibits poor solubility, chemical engineers and solid-state scientists deploy two primary crystalline modifications to enhance aqueous solubility without modifying the covalent drug molecule:

1. Pharmaceutical Salts: Complete proton transfer between the API and an ionizable counterion, forming an ionic crystal lattice held together by strong Coulombic attractions.
2. Pharmaceutical Cocrystals: Non-ionized stoichiometric multi-component crystalline complexes held together by neutral non-covalent interactions (such as directional hydrogen bonds and $\pi$-$\pi$ stacking).

┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
│                               PHARMACEUTICAL SALTS VS. COCRYSTALS                                │
├────────────────────────────────┬────────────────────────────────┬────────────────────────────────┤
│ Physicochemical Property       │ Pharmaceutical Salt            │ Pharmaceutical Cocrystal       │
├────────────────────────────────┼────────────────────────────────┼────────────────────────────────┤
│ Inter-molecular Bonding        │ Ionic (Complete proton transfer)│ Neutral Hydrogen / π-π Bonding │
│ Ionization Requirement         │ API must have ionizable pKa    │ Applicable to non-ionizable APIs│
│ ΔpKa Requirement               │ ΔpKa > 2.0 – 3.0 (Salt rule)   │ ΔpKa < 0 – 1.0 (Non-ionized)   │
│ Solubility Enhancement         │ Often 10× – 1,000× (Dramatic!) │ 2× – 50× (Moderate to high)    │
│ Hygroscopicity Risk            │ High (Ionic lattices bind H₂O) │ Generally lower / tunable      │
│ In Vivo Disproportionation     │ Risk of free-form precipitation│ Risk of cocrystal dissociation │
│ Regulatory Pathway (FDA)       │ Distinct chemical entity       │ Similar to API polymorph (QbD) │
└────────────────────────────────┴────────────────────────────────┴────────────────────────────────┘

However, poor counterion selection or unoptimized cocrystal manufacturing can lead to severe scale-up failures: spontaneous disproportionation in wet granulations, polymorphic transitions during milling, severe deliquescence during storage, or genotoxic sulfonate ester formation in alcohol solvents.

This publication provides the complete chemical engineering framework for mastering the $\Delta\text{p}K_a$ continuum, constructing ternary phase solubility diagrams, and designing robust industrial crystallization processes.

# 1. The Ionization Continuum & The $\Delta\text{p}K_a$ Rule

The boundary between a salt (ionized) and a cocrystal (non-ionized) is not a rigid dividing line, but a continuous thermodynamic spectrum governed by the difference in acid dissociation constants ($\Delta\text{p}K_a$):

                       THE ΔpKa CONTINUUM OF SOLID FORMS
 ┌──────────────────────────────────────────────────────────────────────────────────────────────────┐
 │                                                                                                  │
 │  ΔpKa < 0                 0 ≤ ΔpKa ≤ 2 – 3                   ΔpKa > 3                            │
 │  [PURE COCRYSTAL]         [THE "GREY ZONE"]                  [TRUE PHARMACEUTICAL SALT]          │
 │  No proton transfer.      Partial proton transfer /          Complete proton transfer.           │
 │  Neutral H-bonding.       Temperature-dependent continuum.   Ionic crystal lattice.              │
 │                                                                                                  │
 │  Example:                 Example:                           Example:                            │
 │  Carbamazepine :          Theophylline : 5-Chlorosalicylic   Sertraline Hydrochloride            │
 │  Nicotinamide             Acid Complex (Proton localized)    (ΔpKa ≈ 9.5 - (-7.0) = 16.5)        │
 │                                                                                                  │
 └──────────────────────────────────────────────────────────────────────────────────────────────────┘

# 1.1 The $\Delta\text{p}K_a > 3$ Rule of Thumb

• $\Delta\text{p}K_a > 3.0$: Complete thermodynamic proton transfer is assured across all standard operating temperatures ($0^\circ\text{C} - 80^\circ\text{C}$). A single-phase ionic salt crystallizes reliably.
• $0 < \Delta\text{p}K_a < 3.0$ (The Intermediate "Grey Zone"): Salt vs. cocrystal status depends on solvent dielectric constant, crystal packing energy, and temperature. Single-crystal X-ray diffraction (SC-XRD) or solid-state NMR ($^{15}\text{N}$ / $^{13}\text{C}$ ssNMR) is required to locate proton position.
• $\Delta\text{p}K_a < 0$: Proton transfer is thermodynamically unfavorable. Crystals formed are neutral cocrystals.

# 2. Industrial Counterion Selection Matrix

Selecting a salt counterion requires balancing solubility enhancement, crystallinity, hygroscopicity, toxicology, and chemical stability:

┌─────────────────────────┬─────────────────────────┬─────────────────────────┬─────────────────────────┐
│ Counterion Class        │ Common Examples         │ Key Advantages          │ Engineering Risks       │
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Inorganic Acids         │ Hydrochloride (HCl),    │ High crystalline melting│ Corrosive to SS316L;    │
│                         │ Sulfate (H₂SO₄),        │ point; inexpensive;     │ Common-Ion effect in    │
│                         │ Phosphate (H₃PO₄)       │ well-precedented        │ gastric juice (0.1M HCl)│
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Sulfonic Acids          │ Methanesulfonate (Mes.),│ Exceptional aqueous     │ Potential formation of  │
│                         │ Besylate, Tosylate      │ solubility; fast        │ genotoxic alkyl mesylate│
│                         │                         │ dissolution kinetics    │ esters in alcohols!     │
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Dicarboxylic Acids      │ Maleate, Fumarate,      │ Good stability;         │ Prone to isomerization  │
│                         │ Tartrate, Succinate     │ intermediate polarity;  │ (e.g., maleate to       │
│                         │                         │ low hygroscopicity      │ fumarate); esterification│
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Inorganic Bases         │ Sodium (Na⁺),           │ Readily available;      │ High hygroscopicity /   │
│ (For Acidic APIs)       │ Potassium (K⁺),         │ massive solubility boost│ deliquescence; basic    │
│                         │ Calcium (Ca²⁺)          │ for carboxylic acids    │ microenvironment        │
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Organic Amines          │ Meglumine, Tromethamine,│ Non-hygroscopic salts   │ Bulky counterion lowers │
│ (For Acidic APIs)       │ Choline, L-Arginine     │ for fragile APIs        │ drug loading in tablets │
└─────────────────────────┴─────────────────────────┴─────────────────────────┴─────────────────────────┘

Alkyl sulfonates are potent mutagenic impurities regulated under ICH M7 with strict Threshold of Toxicological Concern (TTC) limits (often $< 1.5\,\mu\text{g/day}$, corresponding to $< 1.5 - 5\,\text{ppm}$ in the API).
Engineering Remedy: Strictly avoid alcohol solvents during final salt formation, or ensure a verified stoichiometric excess of base ($> 1.05\,\text{equiv}$) with controlled water content to push equilibrium back toward free sulfonic acid.

# 3. Ternary Phase Solubility Diagrams: Congruent vs. Incongruent Dissolution

Cocrystal and salt crystallization processes are ternary systems consisting of [API Component A] + [Coformer/Counterion Component B] + [Solvent S].

Designing a continuous or batch crystallization process requires constructing a Ternary Phase Diagram at target operating temperatures ($T$):

                   TERNARY PHASE DIAGRAM: CONGRUENT VS. INCONGRUENT
                              Solvent S (100%)
                                     ▲
                                    / \
                                   /   \
                                  /  L  \  (L = Unsaturated Solution)
                                 /       \
      API Solubility ──►        / \     / \  ◄── Coformer Solubility
      Line in Solvent          /   \   /   \     Line in Solvent
                              /  A+L\ / B+L \
                             /       X       \
                            /       / \       \
                           /  A+AB /   \ AB+B  \
                          /       /     \       \
                         /_______/   AB  \_______\
                       API (A)  ◄── Cocrystal ──► Coformer (B)
                                   Phase (AB)

# 3.1 Congruent vs. Incongruent Dissolution Behavior

• Congruent System: The solubility of the individual API ($A$) and coformer ($B$) in the chosen solvent are balanced ($S_A \approx S_B$). The cocrystal phase ($AB$) dissolves without precipitating either component. The stoichiometric solution (1:1 molar ratio) lies directly in the stable $AB$ crystallization window.
• Incongruent System: One component is significantly more soluble in the solvent than the other ($S_B \gg S_A$). Dissolving pure cocrystal ($AB$) causes immediate precipitation of pure API ($A$) as a thermodynamically stable solid!

┌─────────────────────────────────┬─────────────────────────────────┬─────────────────────────────────┐
│ System Type                     │ Solubility Ratio (S_B / S_A)    │ Crystallization Operational Rule│
├─────────────────────────────────┼─────────────────────────────────┼─────────────────────────────────┤
│ Congruent Crystallization       │ 0.2 < S_B / S_A < 5.0           │ Add stoichiometric 1:1 API and  │
│                                 │ (Balanced solubility)           │ Coformer; cooling or antisolvent│
├─────────────────────────────────┼─────────────────────────────────┼─────────────────────────────────┤
│ Incongruent Crystallization     │ S_B / S_A > 10.0 or < 0.1       │ Must charge a non-stoichiometric│
│                                 │ (Severe solubility mismatch)    │ excess of the more soluble      │
│                                 │                                 │ coformer (e.g., 3:1 Coformer:API)│
└─────────────────────────────────┴─────────────────────────────────┴─────────────────────────────────┘

# 4. In Vivo Disproportionation & The Common-Ion Effect

# 4.1 The Gastric Common-Ion Trap for Hydrochloride Salts

Hydrochloride ($\text{HCl}$) salts represent over $50\%$ of all commercial pharmaceutical salts due to low raw material cost and high crystallization yields.

However, in human gastric fluid, the physiological chloride ion concentration is high ($[\text{Cl}^-] \approx 0.1 - 0.15\,\text{M}$ from endogenous gastric $\text{HCl}$).

According to the Solubility Product ($K_{\text{sp}}$):

As $[\text{Cl}^-]$ increases in the stomach, the equilibrium concentration of ionized drug $[\text{API-H}^+]$ is forced downward:

This Common-Ion Effect can suppress the apparent solubility of an $\text{HCl}$ salt in gastric fluid by $80 - 95\%$, precipitating an insoluble dense hydrochloride skin or free base that prevents drug absorption.

# 4.2 In Vivo Disproportionation and $\text{pH}_{\text{max}}$

For an API salt, the $\text{pH}_{\text{max}}$ is the critical boundary pH where the free base (or free acid) and the salt form have identical equilibrium solubilities:

Where $S_0$ is the intrinsic solubility of the un-ionized free base.

• At $\text{pH} < \text{pH}_{\text{max}}$: The salt is the thermodynamically stable solid phase.
• At $\text{pH} > \text{pH}_{\text{max}}$: The free base is the thermodynamically stable phase; the salt spontaneously disproportionates into free base.

       SOLUBILITY PROFILE VS. PH AND DISPROPORTIONATION BOUNDARY (pH_max)
   Total Solubility S_tot (mg/mL)
     ▲
     │  Ionized Salt Region (pH < pH_max)
     │  \
     │   \
     │    \
     │     \                 pH_max (Critical Boundary Point)
     │      \               │
     │       \              ▼
     │        \            ╭──────────────── Free Base Region (pH > pH_max)
     │         \         ╭─╯                 Thermodynamic Disproportionation Zone!
     │          ╰────────╯                   S_tot = S_0 (Low solubility)
     └──────────────────────────────────────────────────────────► pH
                1        3        5        7        9

If a basic API salt with $\text{pH}_{\text{max}} = 4.2$ enters intestinal fluid ($\text{pH} \approx 6.5$), or is blended with basic formulation excipients (e.g., magnesium stearate or calcium phosphate) in a moist tablet core, it will spontaneously convert into the insoluble free base, completely stalling bioavailability.

# 5. Industrial Crystallization Scale-Up: Step-by-Step Protocol

┌─────────────────────────┬─────────────────────────┬─────────────────────────┬─────────────────────────┐
│ Process Stage           │ Critical Objective      │ Laboratory Method       │ Plant Scale-Up Control  │
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Stage 1: pKa &          │ Identify potential      │ Potentiometric titration│ Filter counterions by   │
│ Counterion Triage       │ salt counterions        │ or computational pKa    │ safety profile (GRAS list)│
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Stage 2: Ternary Phase  │ Determine congruent vs. │ High-throughput robotic │ Establish operating seed│
│ Mapping                 │ incongruent boundaries  │ solubility screening    │ window and cooling curve│
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Stage 3: Seeding &      │ Prevent spontaneous oil-│ Focused Beam Reflectance│ Add 1.0 – 2.0 wt%       │
│ Nucleation Control      │ ing out / free-form nuclea│ (FBRM) & PVM imaging  │ authentic salt seeds    │
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Stage 4: Washing &      │ Remove mother liquor    │ Slurry wash profiling   │ Use saturated wash or   │
│ Deliquoring             │ without disproportion   │                         │ non-polar antisolvent   │
├─────────────────────────┼─────────────────────────┼─────────────────────────┼─────────────────────────┤
│ Stage 5: Vacuum Drying  │ Desorb solvents without │ Dynamic Vapor Sorption  │ Maintain T_dryer < T_des│
│                         │ counterion loss (HCl gas)│ (DVS) & TGA-MS         │ under inert N₂ sweep    │
└─────────────────────────┴─────────────────────────┴─────────────────────────┴─────────────────────────┘

# 6. Key Chemical Engineering Rules of Thumb

1. The $\Delta\text{p}K_a > 3$ Rule: Never scale up an ionic salt without verifying that $\Delta\text{p}K_a \ge 3.0$. Operating inside the grey zone ($0 < \Delta\text{p}K_a < 2$) risks batch-to-batch shifts between salt, solvate, and cocrystal.
2. Beware the Common Ion: If developing a hydrochloride salt, always measure solubility in simulated gastric fluid ($0.1\,\text{M}\,\text{HCl}$) in addition to pure water. High common-ion suppression necessitates evaluating alternative counterions (such as mesylates, maleates, or besylates).
3. Incongruent Systems Require Coformer Excess: If ternary mapping reveals an incongruent cocrystal phase diagram, never charge stoichiometric 1:1 components during plant crystallizations; charge a thermodynamic excess ($1.5 - 3.0\,\text{equiv}$) of the more soluble coformer.
4. Washing Safety: Never wash a water-soluble salt cake with pure deionized water in an ANFD or centrifuge; instant dissolution will destroy cake structure and cut yields. Wash exclusively with pre-cooled, saturated mother liquor or an appropriate non-polar antisolvent (e.g., heptane or ethyl acetate).

Published by the PharmaChemEng Technical Editorial Board for pharmaceutical solid-state scientists, crystallization scale-up engineers, and pre-formulation teams.